Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review)
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review)
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF ONCOLOGY
Volume 63, Issue 2, Pages -
Publisher
Spandidos Publications
Online
2023-07-05
DOI
10.3892/ijo.2023.5545
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study
- (2023) Xi Ding et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I study of expanded natural killer cells in combination with cetuximab for recurrent/metastatic nasopharyngeal carcinoma
- (2022) Chwee Ming Lim et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
- (2022) Hussein A. Tawbi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
- (2022) Manali Kamdar et al. LANCET
- TCR engineered T cells for solid tumor immunotherapy
- (2022) Yikai Zhang et al. Experimental Hematology & Oncology
- Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): A prospective phase II randomized controlled study
- (2022) Huageng Huang et al. RADIOTHERAPY AND ONCOLOGY
- Response to Gargi S Sarode, Sachin C Sarode, and Rahul Anand’s Letter to the Editor of Radiotherapy and Oncology regarding the paper titled “Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): A prospective phase II randomized controlled study.” by Huang et al
- (2022) Huageng Huang et al. RADIOTHERAPY AND ONCOLOGY
- Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)
- (2021) Feng-Hua Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- CTLA-4 expression by B-1a B cells is essential for immune tolerance
- (2021) Yang Yang et al. Nature Communications
- Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma
- (2021) Mona M. Ahmed et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
- (2021) Nikhil C. Munshi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy
- (2021) Riyao Yang et al. Nature Communications
- Immunization with Epstein–Barr Virus Core Fusion Machinery Envelope Proteins Elicit High Titers of Neutralizing Activities and Protect Humanized Mice from Lethal Dose EBV Challenge
- (2021) Xinle Cui et al. Vaccines
- Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma
- (2021) Corey Smith et al. npj Precision Oncology
- Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy
- (2021) Ramazan Rezaei et al. CANCER GENE THERAPY
- Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, Versus Chemotherapy in Patients With Recurrent/Metastatic Nasopharyngeal Cancer
- (2021) Caroline Even et al. CLINICAL CANCER RESEARCH
- Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study
- (2021) Shaodong Hong et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
- (2021) Robin Kate Kelley et al. JOURNAL OF CLINICAL ONCOLOGY
- T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors
- (2021) Apostolia-Maria Tsimberidou et al. Journal of Hematology & Oncology
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
- (2021) Jesus G Berdeja et al. LANCET
- Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
- (2021) Yunpeng Yang et al. LANCET ONCOLOGY
- Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial
- (2021) Hai-Qiang Mai et al. NATURE MEDICINE
- Nasopharyngeal carcinoma: an evolving paradigm
- (2021) Kenneth C. W. Wong et al. Nature Reviews Clinical Oncology
- Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
- (2021) Paul Nathan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term Survivals, Toxicities and the Role of Chemotherapy in Early-Stage Nasopharyngeal Carcinoma Patients Treated with Intensity-modulated Radiation Therapy: A Retrospective Study with 15-year Follow-up
- (2021) Lin Wang et al. Cancer Research and Treatment
- Main Targets of Interest for the Development of a Prophylactic or Therapeutic Epstein-Barr Virus Vaccine
- (2021) Vincent Jean-Pierre et al. Frontiers in Microbiology
- Novel strategies for immuno-oncology breakthroughs with cell therapy
- (2021) Hongtao Liu et al. Biomarker Research
- Is Immune Therapy Plus Chemotherapy More Effective Than Immune Therapy Alone for Unresectable Recurrent Nasopharyngeal Carcinoma?
- (2021) Xin Zhou et al. Frontiers in Immunology
- Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases
- (2021) Xinle Cui et al. Frontiers in Immunology
- Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trial
- (2021) Yijun Hua et al. Journal for ImmunoTherapy of Cancer
- Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)
- (2021) Yunpeng Yang et al. Journal for ImmunoTherapy of Cancer
- ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges
- (2020) S. Depil et al. NATURE REVIEWS DRUG DISCOVERY
- CD3+T-lymphocyte infiltration is an independent prognostic factor for advanced nasopharyngeal carcinoma
- (2020) Nasser Al-Rajhi et al. BMC CANCER
- Human chimeric antigen receptor macrophages for cancer immunotherapy
- (2020) Michael Klichinsky et al. NATURE BIOTECHNOLOGY
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
- (2020) Michael Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma
- (2020) Yu-Pei Chen et al. CELL RESEARCH
- Novel Therapies Boosting T Cell Immunity in Epstein Barr Virus-Associated Nasopharyngeal Carcinoma
- (2020) Sarah Renaud et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Galectin-9 promotes a suppressive microenvironment in human cancer by enhancing STING degradation
- (2020) Chuan-xia Zhang et al. Oncogenesis
- Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
- (2020) Lin Shen et al. Journal for ImmunoTherapy of Cancer
- CAR-NK cells: A promising cellular immunotherapy for cancer
- (2020) Guozhu Xie et al. EBioMedicine
- Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy
- (2019) Quynh Thu Le et al. JNCI-Journal of the National Cancer Institute
- Prophylactic and therapeutic strategies for Epstein–Barr virus-associated diseases: emerging strategies for clinical development
- (2019) Vijayendra Dasari et al. Expert Review of Vaccines
- A Phase I/II Open‐Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors
- (2019) Yuxiang Ma et al. ONCOLOGIST
- Nasopharyngeal carcinoma
- (2019) Yu-Pei Chen et al. LANCET
- Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy
- (2019) Xiaojie Yu et al. mAbs
- Genome sequencing analysis identifies Epstein–Barr virus subtypes associated with high risk of nasopharyngeal carcinoma
- (2019) Miao Xu et al. NATURE GENETICS
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Translational genomics of nasopharyngeal cancer
- (2019) Chi Man Tsang et al. SEMINARS IN CANCER BIOLOGY
- Significance of TIM3 expression in cancer: From biology to the clinic
- (2019) Cinzia Solinas et al. SEMINARS IN ONCOLOGY
- CD137 Co-Stimulation Improves The Antitumor Effect Of LMP1-Specific Chimeric Antigen Receptor T Cells In Vitro And In Vivo
- (2019) Xiaojun Tang et al. OncoTargets and Therapy
- Modulation of the tumor microenvironment by Epstein-Barr virus latent membrane protein 1 in nasopharyngeal carcinoma
- (2018) Tomokazu Yoshizaki et al. CANCER SCIENCE
- Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians
- (2018) Sophie Outh-Gauer et al. CANCER TREATMENT REVIEWS
- Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)
- (2018) Brigette B.Y. Ma et al. JOURNAL OF CLINICAL ONCOLOGY
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cellular-based immunotherapy in Epstein-Barr virus induced nasopharyngeal cancer
- (2018) Andrea Zhe Ern Lee et al. ORAL ONCOLOGY
- Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
- (2018) Wenfeng Fang et al. LANCET ONCOLOGY
- 10‐Year Results of Therapeutic Ratio by Intensity‐Modulated Radiotherapy Versus Two‐Dimensional Radiotherapy in Patients with Nasopharyngeal Carcinoma
- (2018) Lei Chen et al. ONCOLOGIST
- Tim-3 and its role in regulating anti-tumor immunity
- (2017) Madhumita Das et al. IMMUNOLOGICAL REVIEWS
- CIK as therapeutic agents against tumors
- (2017) M. Introna JOURNAL OF AUTOIMMUNITY
- Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
- (2017) Chiun Hsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations
- (2017) Yvonne Y Li et al. Nature Communications
- A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors
- (2017) Riccardo Turrini et al. OncoImmunology
- Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response
- (2017) Corey Smith et al. OncoImmunology
- 5T4-specific chimeric antigen receptor modification promotes the immune efficacy of cytokine-induced killer cells against nasopharyngeal carcinoma stem cell-like cells
- (2017) Xueyang Guo et al. Scientific Reports
- The immunologic advantage of recurrent nasopharyngeal carcinoma from the viewpoint of Galectin-9/Tim-3-related changes in the tumour microenvironment
- (2017) Tseng-Cheng Chen et al. Scientific Reports
- Cancer immunotherapy: the beginning of the end of cancer?
- (2016) Sofia Farkona et al. BMC Medicine
- Oral Hygiene and Risk of Nasopharyngeal Carcinoma--A Population-Based Case-Control Study in China
- (2016) Z. Liu et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- The Basis of Oncoimmunology
- (2016) A. Karolina Palucka et al. CELL
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- Phase I Clinical Trial of 4-1BB-based Adoptive T-Cell Therapy for Epstein-Barr Virus (EBV)-positive Tumors
- (2016) Hyeon-Seok Eom et al. JOURNAL OF IMMUNOTHERAPY
- Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial
- (2016) Li Zhang et al. LANCET
- The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
- (2016) Danny N. Khalil et al. Nature Reviews Clinical Oncology
- Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350
- (2016) Xinle Cui et al. VACCINE
- Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy
- (2015) Jian Ji Pan et al. CANCER
- Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade
- (2015) Elizabeth Buchbinder et al. JOURNAL OF CLINICAL INVESTIGATION
- Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
- (2015) Lieping Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Significance of Tumor Volume in Locally Recurrent Nasopharyngeal Carcinoma Treated with Salvage Intensity-Modulated Radiotherapy
- (2015) WeiWei Xiao et al. PLoS One
- Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma
- (2015) Jiang Li et al. OncoImmunology
- Sequential Cytokine-Induced Killer Cell Immunotherapy Enhances the Efficacy of the Gemcitabine Plus Cisplatin Chemotherapy Regimen for Metastatic Nasopharyngeal Carcinoma
- (2015) Yin Li et al. PLoS One
- A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein-Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer
- (2014) G. S. Taylor et al. CLINICAL CANCER RESEARCH
- Etiological factors of nasopharyngeal carcinoma
- (2014) Sai Wah Tsao et al. ORAL ONCOLOGY
- Epstein Barr virus entry; kissing and conjugation
- (2014) Claire Shannon-Lowe et al. Current Opinion in Virology
- An oncolytic adenovirus enhances antiangiogenic and antitumoral effects of a replication-deficient adenovirus encoding endostatin by rescuing its selective replication in nasopharyngeal carcinoma cells
- (2013) Ran-yi Liu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Epstein-Barr virus nuclear antigen 1 (EBNA1) protein induction of epithelial-mesenchymal transition in nasopharyngeal carcinoma cells
- (2013) Lu Wang et al. CANCER
- Phase I Trial of Recombinant Modified Vaccinia Ankara Encoding Epstein-Barr Viral Tumor Antigens in Nasopharyngeal Carcinoma Patients
- (2013) E. P. Hui et al. CANCER RESEARCH
- Cytotoxic T Cell Adoptive Immunotherapy as a Treatment for Nasopharyngeal Carcinoma
- (2013) Viviana P. Lutzky et al. Clinical and Vaccine Immunology
- Delayed-type Hypersensitivity (DTH) Immune Response Related With EBV-DNA in Nasopharyngeal Carcinoma Treated With Autologous Dendritic Cell Vaccination After Radiotherapy
- (2013) Feng Li et al. JOURNAL OF IMMUNOTHERAPY
- Adoptive T-cell Transfer and Chemotherapy in the First-line Treatment of Metastatic and/or Locally Recurrent Nasopharyngeal Carcinoma
- (2013) Whay-Kuang Chia et al. MOLECULAR THERAPY
- A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
- (2013) Taku Okazaki et al. NATURE IMMUNOLOGY
- A novel tetrameric gp3501–470 as a potential Epstein–Barr virus vaccine
- (2013) Xinle Cui et al. VACCINE
- Effective Treatment of Metastatic Forms of Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma with a Novel Adenovirus-Based Adoptive Immunotherapy
- (2012) C. Smith et al. CANCER RESEARCH
- Antitumor Effects of Interferon-Alpha on Cell Growth and Metastasis in Human Nasopharyngeal Carcinoma
- (2012) X. Liu et al. CURRENT CANCER DRUG TARGETS
- Long-term treatment outcome of recurrent nasopharyngeal carcinoma treated with salvage intensity modulated radiotherapy
- (2012) Yi-Jun Hua et al. EUROPEAN JOURNAL OF CANCER
- Autologous Cytokine-induced Killer Cell Transfusion in Combination With Gemcitabine Plus Cisplatin Regimen Chemotherapy for Metastatic Nasopharyngeal Carcinoma
- (2012) Jian-jun Li et al. JOURNAL OF IMMUNOTHERAPY
- Host–tumor interactions in nasopharyngeal carcinomas
- (2012) Claire Gourzones et al. SEMINARS IN CANCER BIOLOGY
- Deciphering the molecular genetic basis of NPC through molecular, cytogenetic, and epigenetic approaches
- (2012) Kwok-Wai Lo et al. SEMINARS IN CANCER BIOLOGY
- T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results
- (2011) S. Secondino et al. ANNALS OF ONCOLOGY
- A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma
- (2011) W. K. Chia et al. ANNALS OF ONCOLOGY
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- Anti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma
- (2011) Jia-Ni Wang et al. Chinese Journal of Cancer
- The PD-1 pathway in tolerance and autoimmunity
- (2010) Loise M. Francisco et al. IMMUNOLOGICAL REVIEWS
- Adoptive Transfer of EBV-specific T Cells Results in Sustained Clinical Responses in Patients With Locoregional Nasopharyngeal Carcinoma
- (2010) Chrystal U. Louis et al. JOURNAL OF IMMUNOTHERAPY
- Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBV-encoded oncogene LMP-1 through self-aggregation
- (2009) C. Smith et al. BLOOD
- Functional polymorphism ofcytotoxic T-lymphocyte antigen 4and nasopharyngeal carcinoma susceptibility in a Chinese population
- (2009) M. Xiao et al. International Journal of Immunogenetics
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search